Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Rani Therapeutics Holdings Inc shares valued at $1,260,417 were purchased by IMRAN MIR A on Oct 23 ’25. At $0.60 per share, IMRAN MIR A acquired 2,083,334 shares. The insider’s holdings grew to 2,083,334 shares worth approximately $2.81 million following the completion of this transaction.
Also, South Cone Investments Limited sold 4,000,000 shares, netting a total of over 11,074,000 in proceeds. Following the sale of shares at $2.77 each, the insider now holds 2,379,194 shares.
Before that, South Cone Investments Limited had sold 1,923,000 shares from its account. In a trade valued at $4,637,314, the 10% Owner traded Rani Therapeutics Holdings Inc shares for $2.41 each. Upon closing the transaction, the insider’s holdings decreased to 1,923,000 shares, worth approximately $8.61 million.
As published in their initiating research note from Oppenheimer on August 02, 2024, Rani Therapeutics Holdings Inc [RANI] has been an Outperform and the price target has been revised to $17. Analysts at Maxim Group started covering the stock with ‘”a Buy”‘ outlook in a report released in mid June. As of June 13, 2024, Rodman & Renshaw has initiated its “Buy” rating for RANI.
Analyzing RANI Stock Performance
On last trading session, Rani Therapeutics Holdings Inc [NASDAQ: RANI] plunged -0.74% to $1.35. The stock’s lowest price that day was $1.31, but it reached a high of $1.37 in the same session. During the last five days, there has been a drop of approximately -4.93%. Over the course of the year, Rani Therapeutics Holdings Inc shares have jumped approximately 3.05%.
Is Rani Therapeutics Holdings Inc subject to short interest?
Stocks of Rani Therapeutics Holdings Inc saw a sharp rise in short interest on 2025-12-31 jumping by 3.28 million shares to 13.89 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 10.6 million shares. A jump of 23.65% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 5.43 of the overall float, the days-to-cover ratio (short ratio) jumped to 5.43.
Which companies own the most shares of Rani Therapeutics Holdings Inc (RANI)?
In terms of Rani Therapeutics Holdings Inc share price expectations, FactSet research, analysts set an average price target of 10 in the next 12 months, up nearly 635.29% from the previous closing price of $1.36. Analysts anticipate Rani Therapeutics Holdings Inc stock to reach 28 by 2026, with the lowest price target being 9. In spite of this, 3 analysts ranked Rani Therapeutics Holdings Inc stock as Buy at the end of 2026. On October 11, 2022, UBS assigned a price target of “a Buy” to the stock and initiated coverage with a $15.
